Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $9.00 price objective on the stock. HC Wainwright's target price indicates a potential upside of 312.84% from the stock's previous close.
Cardiol Therapeutics Stock Performance
NASDAQ CRDL remained flat at $2.18 on Tuesday. 352,593 shares of the company's stock were exchanged, compared to its average volume of 359,085. The firm's 50 day moving average price is $1.78 and its 200-day moving average price is $1.31. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.36 and a quick ratio of 4.36. The firm has a market cap of $148.85 million, a price-to-earnings ratio of -6.61 and a beta of 0.87. Cardiol Therapeutics has a 12 month low of $0.55 and a 12 month high of $2.25.
Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last issued its quarterly earnings results on Monday, April 1st. The company reported ($0.09) earnings per share (EPS) for the quarter. Sell-side analysts forecast that Cardiol Therapeutics will post -0.25 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Cardiol Therapeutics stock. Laird Norton Trust Company LLC boosted its holdings in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) by 63.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,000 shares of the company's stock after buying an additional 38,673 shares during the quarter. Laird Norton Trust Company LLC owned approximately 0.15% of Cardiol Therapeutics worth $90,000 as of its most recent SEC filing. Institutional investors own 12.49% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Further Reading
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
